U.S. Personal Products Stock News

In recent weeks, Olema Pharmaceuticals announced the departure of its COO and CFO, Shane Kovacs, who will remain as a consultant through August 1, 2026, while CEO Sean Bohen temporarily assumes principal financial officer responsibilities. At the same time, continued Buy ratings from Citi and new coverage from Stifel have put a spotlight on palazestrant’s commercial potential in the sizeable endocrine therapy market and growing hedge fund interest in the stock. With this context, we’ll...

In late February 2026, NovoCure reported fourth-quarter 2025 revenue of US$174.35 million and a quarterly loss of US$24.5 million, alongside full-year 2025 revenue of US$655.35 million and a narrowed annual loss of US$136.23 million, while issuing 2026 net revenue guidance of US$675 million to US$705 million. Alongside these results, NovoCure secured U.S. FDA approval and began the commercial launch of Optune Pax for locally advanced pancreatic cancer, signaling a shift from a...

In recent months, Scorpio Tankers reported strong fourth-quarter results, with net income rising to US$128.1 million and daily TCE rates increasing year over year, while shifting its balance sheet from US$3.10 billions in net debt in 2021 to roughly US$334 million in net cash by early 2026. The company complemented this financial improvement with a higher quarterly dividend of US$0.45 per share and continued investment in scrubber-fitted vessels, pointing to a focus on cash returns and...

Turan Drilling and Engineering Company LLC, the joint venture between Helmerich & Payne and bp, recently secured a renewed offshore operations and maintenance contract from bp in the Caspian Sea, offshore Azerbaijan, with a firm 5-year term and three optional 1-year extensions that together could exceed US$1.00 billion in value. This long-term renewal underscores how Helmerich & Payne’s partnership role with bp in the Caspian Sea may support more predictable revenue and operational...

Preferred Bank (PFBC) has drawn fresh attention after recent trading left the stock around $87.72. Mixed returns over the past week, month and past 3 months are prompting investors to reassess its current valuation. See our latest analysis for Preferred Bank. The recent 1 day share price decline of 3.36% and year to date share price return of negative 8.57% contrast with a 1 year total shareholder return of 3.12%. This suggests shorter term momentum has cooled even as longer term holders have...

Dyne Therapeutics, Inc. reported a full-year 2025 net loss of US$446.21 million, with basic and diluted loss per share from continuing operations of US$3.47, and also filed a US$128.83 million shelf registration for 8,247,527 common shares related to its employee stock ownership plans. Amid this widening loss, Dyne is progressing its neuromuscular pipeline, including plans to seek U.S. Accelerated Approval for z-rostudirsen in Duchenne muscular dystrophy, which highlights how funding moves...

Madison Square Garden Entertainment Corp. recently disclosed that a data breach discovered on or about December 16, 2025 exposed personal information via a vulnerability in Oracle’s eBusiness Suite, prompting legal investigations by Edelson Lechtzin LLP on behalf of affected individuals. Beyond potential legal and remediation costs, this incident puts the company’s data security and operational controls under scrutiny at a time when it relies heavily on customer trust for its live...

F&G Annuities & Life, Inc. and Voya Financial, Inc. previously announced that F&G’s annuity solutions would be distributed through Voya’s Wealth Management platform, giving Voya financial professionals access to F&G products, education and support for retirement and income protection planning. This collaboration combines F&G’s product range with Voya’s advisory reach, potentially broadening F&G’s presence in the US retirement market and deepening advisor adoption of its annuity...

Relay Therapeutics, Inc. recently reported full-year 2025 results, with revenue rising to US$15.36 million from US$10.01 million and its net loss narrowing to US$276.48 million from US$337.71 million, while also securing FDA Breakthrough Therapy designation and advancing multiple 2026 data milestones for lead asset zovegalisib. Alongside a narrower basic loss per share of US$1.61 versus US$2.36 a year earlier, the company filed a US$96.18 million common-stock shelf registration tied to an...

Astec Industries, Inc. has now reported its fourth-quarter and full-year 2025 results, with Q4 sales rising to US$400.6 million from US$359.0 million and full-year sales reaching US$1.41 billion, while net income increased to US$38.8 million for 2025 and the Board maintained a quarterly dividend of US$0.13 per share payable in March 2026. Despite Q4 net income easing year on year, the company delivered record quarterly and annual sales, beat analyst earnings and revenue expectations,...

IMAX Corporation recently reported fourth-quarter 2025 revenue of US$125.21 million and full-year 2025 revenue of US$410.21 million, with annual net income rising to US$34.88 million even as quarterly net income softened. The company paired these record box office and revenue results with ongoing global network expansion and deeper local-language and live-event content partnerships, including a new collaboration with Apple TV to screen select 2026 Formula One races in IMAX theaters. We’ll...

What Pfizer’s Recent Share Performance Signals for Investors With no single headline event driving the move, Pfizer (PFE) has quietly posted positive returns over the past week, month, and past 3 months. This naturally raises questions about what is being priced into the stock. See our latest analysis for Pfizer. At a share price of $27.65, Pfizer’s recent 1 day share price return of 2.03%, 30 day share price return of 4.58%, and roughly 10% year to date share price return suggest momentum...

Chemed Corporation recently reported fourth-quarter 2025 results showing net income of US$76.75 million and full-year 2025 net income of US$265.24 million, both lower than the prior year, alongside 2026 adjusted earnings guidance of US$23.25–US$24.25 per diluted share. Despite ongoing share repurchases totaling US$2.62 billion since 2011, investors focused on pressure in VITAS and Roto-Rooter margins, including Medicare Cap constraints and water-restoration write-offs. We’ll now examine how...

In February 2026, Guardant Health reported fourth-quarter 2025 revenue of US$281.27 million and a net loss of US$128.49 million, filed a US$510.17 million shelf registration for 4,795,700 common shares tied to employee stock plans, and issued 2026 revenue guidance of US$1.25–1.28 billion. Alongside these filings and results, Guardant’s inclusion as a leading contributor in an institutional growth fund and commentary about volume-driven expansion and acquisition activity highlighted growing...

Jehoshaphat Research’s short report on GPGI (GPGI), centered on alleged overstatement of Husky Technologies’ financial metrics and the abrupt CEO and CFO resignations, has quickly become a key focus for traders assessing the stock. See our latest analysis for GPGI. GPGI’s latest short report comes after a year where the share price has moved sharply at times, with a 20.25% year to date share price return and a very large 3 year total shareholder return of about 4x. This is even with a recent...

In late February 2026, Mirum Pharmaceuticals reported Q4 2025 revenue of US$148.93 million and a quarterly net loss of US$5.73 million, alongside filing shelf registrations to potentially issue up to 12,074,780 new common shares worth about US$1.30 billion. While these results showed a smaller annual net loss of US$23.36 million on full-year revenue of US$521.31 million, the large prospective equity issuance raised fresh questions about dilution and how Mirum plans to finance its ongoing...

WEBTOON Entertainment (WBTN) is back in focus as markets weigh expectations for its upcoming earnings, with forecasts pointing to a quarterly loss and year over year declines in revenue and several key business segments. See our latest analysis for WEBTOON Entertainment. At a latest share price of $11.25, WEBTOON Entertainment has a 1 year total shareholder return of 26.4%, while its year to date share price return of 14.8% and 90 day share price return of 19.1% suggest momentum has cooled...

In February 2026, The Allstate Corporation declared approximately US$29.3 million in cash dividends on its Series H, I and J preferred stock for the January 15 to April 14 period, payable on April 15 to stockholders of record on March 31, alongside board approval of a higher quarterly common dividend of US$1.08 per share. This combination of stronger earnings, improved auto and homeowners loss ratios, and increased common and preferred dividends underlines management’s confidence in the...

Green Brick Partners, Inc. reported fourth-quarter 2025 revenue of US$552.61 million and net income of US$78.37 million, with full-year revenue of about US$2.10 billion and net income of US$313.23 million, while its board authorized a new US$150 million share repurchase program and continued quarterly dividends on its Series A preferred stock. Despite year-on-year declines in quarterly and full-year earnings per share, Green Brick posted record fourth-quarter home deliveries and net orders,...

Tarsus Pharmaceuticals (TARS) recently reported full year 2025 results, with revenue of US$451.36 million and a net loss of US$66.42 million, and also filed a US$141.73 million shelf registration. See our latest analysis for Tarsus Pharmaceuticals. The latest earnings improvement and governance changes appear to sit behind a strong share price recovery, with a 30 day share price return of 17.01% and a one year total shareholder return of 76.78%. This is despite the year to date share price...

In February 2026, Copart, Inc. reported that its second-quarter revenue slipped to US$1,121.67 million from US$1,163.32 million a year earlier, with net income easing to US$350.73 million and diluted earnings per share from continuing operations at US$0.36 versus US$0.40. An interesting contrast is that while quarterly revenue and profit dipped year over year, Copart’s net income for the first half of the fiscal year edged up slightly to US$754.45 million, with earnings per share essentially...

QuidelOrtho (QDEL) has drawn fresh investor attention after announcing a long-term supply agreement with Lifotronic Technology, giving the diagnostics company access to additional immunoassay analyzers and more than 70 assays across select markets outside the United States. See our latest analysis for QuidelOrtho. That supply agreement arrives at a time when QuidelOrtho’s share price has seen a 7.31% 7 day gain to US$22.74, but its year to date share price return of 20.99% and 1 year total...

Earnings and leadership changes draw focus to Erie Indemnity (ERIE) Erie Indemnity (ERIE) has moved into the spotlight after releasing its full year 2025 results, showing revenue of US$4,067.26 million alongside lower net income and earnings per share compared with the prior year. See our latest analysis for Erie Indemnity. Investors have been weighing the full year 2025 results and the planned CEO transition against recent market performance, with the share price at US$269.44 and a 1 year...

Aehr Test Systems recently announced a US$14,000,000 order from its lead AI processor customer for multiple fully automated FOX-XP wafer-level test and burn-in systems, WaferPak contactors, and Auto Aligners to support data center AI applications, with shipments expected within six months. This deal expands the customer’s automated wafer-level burn-in capacity and underscores Aehr’s role in providing reliability-focused test equipment for high-power AI processors. We’ll now examine how this...